Literature DB >> 10492192

Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.

C R Pound1, O W Christens-Barry, R T Gurganus, A W Partin, P C Walsh.   

Abstract

PURPOSE: We determine the probability of local or distant recurrence following radical prostatectomy in men with an undetectable prostate specific antigen (PSA) level.
MATERIALS AND METHODS: The clinical course of 1,916 consecutive men followed during a 14-year period after radical prostatectomy was reviewed. Average followup plus or minus standard deviation is 5.5+/-3.5 years, and 326 men (17%) have been followed for more than 10 years. In total this population of men has been followed for 10,540 patient-years.
RESULTS: Of 1,916 men 56 (2.9%) had local recurrence an average of 6.1+/-2.7 years (range 1 to 12) after surgery. No man had local recurrence with an undetectable serum PSA. Mean serum PSA at the time of local recurrence was 5.8 ng./ml. Of the 56 men 13 (25%) who had local disease recurrence had an undetectable serum PSA at 5 years of followup but had progression to biochemical and local disease recurrence later. Of 1,916 men 118 had distant metastases with a mean serum PSA of 28.6 ng./ml. No man has had distant metastasis with an undetectable serum PSA.
CONCLUSIONS: Disease can recur after radical prostatectomy even after an extended biochemical disease-free interval. None of the 1,916 men followed for an average of greater than 5 years after surgery had local recurrence or distant metastasis with an undetectable serum PSA. Based on these observations, we recommend no further evaluation, that is digital rectal examination or imaging studies, in men with an undetectable PSA following radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492192

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].

Authors:  M P Wirth; F M Engelhardt
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 2.  Best practice in primary care pathology: review 4.

Authors:  W S A Smellie; J Forth; S Sundar; E Kalu; C A M McNulty; E Sherriff; I D Watson; C Croucher; T M Reynolds; P J Carey
Journal:  J Clin Pathol       Date:  2006-05-19       Impact factor: 3.411

3.  Best of the 1999 AUA Annual Meeting: Highlights from the American Urological Association Annual Meeting May 1-6, 1999, Dallas, Texas.

Authors: 
Journal:  Rev Urol       Date:  1999

4.  Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.

Authors:  Chiachien Jake Wang; James Ying; Payal Kapur; Bryan Wohlfeld; Claus Roehrborn; Dong W Nathan Kim
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

5.  A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Authors:  C J Paller; X Ye; P J Wozniak; B K Gillespie; P R Sieber; R H Greengold; B R Stockton; B L Hertzman; M D Efros; R P Roper; H R Liker; M A Carducci
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-06-12       Impact factor: 5.554

6.  Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.

Authors:  C R Pound; M K Brawer; A W Partin
Journal:  Rev Urol       Date:  2001

Review 7.  Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).

Authors:  Pasquale Martino; Vincenzo Scattoni; Andrea B Galosi; Paolo Consonni; Carlo Trombetta; Silvano Palazzo; Carmen Maccagnano; Giovanni Liguori; Massimo Valentino; Michele Battaglia; Libero Barozzi
Journal:  World J Urol       Date:  2011-05-08       Impact factor: 4.226

Review 8.  Salvage radiotherapy following radical prostatectomy.

Authors:  Charles Catton; Michael Milosevic
Journal:  World J Urol       Date:  2003-08-16       Impact factor: 4.226

9.  Is DRE essential for the follow up of prostate cancer patients? A prospective audit of 194 patients.

Authors:  Narasimhan Ragavan; Vijay K Sangar; Sujoy Gupta; Jennifer Herdman; Shyam S Matanhelia; Michael E Watson; Rosemary A Blades
Journal:  BMC Urol       Date:  2005-01-10       Impact factor: 2.264

Review 10.  What does prostate-specific antigen recurrence mean?

Authors:  C R Pound; A W Partin
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.